Press release
March 5, 2026
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Metagenomi Therapeutics, Inc. (MGX)
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026 Announced corporate name change to Metagenomi